Innospec Stock Hits New 52-Week High (IOSP)

NEW YORK ( TheStreet) -- Innospec (Nasdaq: IOSP) hit a new 52-week high Friday as it is currently trading at $37.60, above its previous 52-week high of $36.44 with 45,179 shares traded as of 10:11 a.m. ET. Average volume has been 132,100 shares over the past 30 days.

Innospec has a market cap of $830.6 million and is part of the basic materials sector and chemicals industry. Shares are up 77.9% year to date as of the close of trading on Thursday.

Innospec Inc. engages in the development, manufacture, blending, and marketing of fuel additives and other specialty chemicals to oil refineries, and other chemical and industrial companies worldwide. The company has a P/E ratio of 11.8, equal to the average chemicals industry P/E ratio and below the S&P 500 P/E ratio of 17.
  • Practice your IOSP trading strategies and win cash in our stock game.

TheStreet Ratings rates Innospec as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Innospec Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI